Risk factors for the development of endometrial lesions in breast cancer patients using tamoxyphen: a retrospective cohort study
breast cancer is the cancer with the highest incidence in women in Brazil, representing 29.7% of all cancers. More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for...
Gespeichert in:
Veröffentlicht in: | Revista do Colegio Brasileiro de Cirurgioes 2023, Vol.50, p.e20233442 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | breast cancer is the cancer with the highest incidence in women in Brazil, representing 29.7% of all cancers. More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for the development of endometrial cancer (four-fold greater relative risk).
this study aimed to evaluate the association of tamoxifen and the development of endometrial disturbances and to assess possible other associated risk factors.
a total of 364 breast cancer patients were evaluated, 286 who used tamoxifen and 78 who did not use this hormone therapy. Results: patients who used tamoxifen had a mean follow-up time of 51.42 months similar to those without hormone therapy (p=0.081). A total of 21 (7.3%) women who used tamofixen and no cases among women without hormone therapy presented endometrial changes during follow-up (p=0.01). Despite information regarding obesity was available for only 270 women, obesity was also significantly associated with the development of endometrial changes (p=0.008).
furthermore, the association between tamofixen and endometrial changes remained significant (p=0.039) after adjusting for obesity. |
---|---|
ISSN: | 0100-6991 1809-4546 |
DOI: | 10.1590/0100-6991e-20233442-en |